USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
US and EU Biotech Industry VC Investment Growth Opportunities
Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI
24-Aug-2021
North America
Market Research
MG49-01-00-00-00
HC03443-NA-MT_25714
$2,450.00
Special Price $1,837.50 save 25 %
With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for industry participants to leverage. Capital flow has grown dramatically in biotech due to emergence of start-ups and small/midsize biotech having advanced techniques involved in next-generation therapies, such as immunotherapies and personalized medicines. In the biopharma sector, companies with platform technology for targeting multiple indications in early clinical and preclinical stages, such as Roviant Sciences, Curevac, and Sana Biotechnology saw the highest investments in 2020.
This report reviews the significant drivers that will propel the VC investment in biotech and specifically CGT. It highlights the dynamics of the Chinese investors in the biotech VC landscape.
Other discussions on the biotech VC investment trend include:
• The healthcare sector VC landscape in the US and EU from 2018 to 2020.
• Key trends in biopharma VC investment.
• Analysis of global biotech VC deals by modality from 2016 to H1 2021.
• Analysis of global biotech VC deals by therapeutic segment from 2016 to H1 2021.
• Analysis of global biotech VC deals by stage of clinical development from 2016 to H1 2021.
• A snapshot of the VC investment trend in the CGT segment.
• The key companies to watch in the CGT space.
• Key growth opportunities paving the way for future VC investment in the biotech industry.
Author: Surbhi Gupta
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on Biotech VC Investment
Growth Opportunities Fuel the Growth Pipeline Engine™
Growth Environment
Growth Drivers for Biotech VC Investment
Growth Restraints for Biotech VC Investment
Healthcare VC Investment Trend in the US and EU
Biopharma VC Investment Trend
Biotech VC Deals Analysis by Modality
Biotech VC Deals Analysis by Stages of Clinical Development
Biotech VC Deals Analysis by Therapeutic Segment
Cell and Gene Therapy VC Investment Trend
AI-enabled Drug Discovery Global Investment Trend
AI-enabled Drug Discovery VC Deals Analysis by Funding Stage
Arcellx, US
Arcellx’s Cell Therapy Pipeline
ElevateBio, US
ElevateBio Portfolio Companies Snapshot—AlloVir
ElevateBio Portfolio Companies Snapshot—HighPassBio
ElevateBio Portfolio Companies Snapshot—LifeEDIT Therapeutics
GraphiteBio, US
Graphite Bio’s Gene Therapy Pipeline
Affinia Therapeutics, US
Affinia Therapeutics’ Gene Therapy Pipeline
Century Therapeutics, US
Century Therapeutics’ Cell Therapy Pipeline
AbCellera Biologics, Canada
Exscientia, United Kingdom
Growth Opportunity 1—Integrated Incubator-CMDO Services for CGT Start-ups and Smaller Biotech Firms
Growth Opportunity 1—Integrated Incubator-CMDO Services for CGT Start-ups and Smaller Biotech Firms (continued)
Traditional CDMO Collaborations to Strengthen CGT Services
Growth Opportunity 2—Strategic Collaborations with Domestic CGT Participants for Success in China CGT Market
Growth Opportunity 2—Strategic Collaborations with Domestic CGT Participants for Success in China CGT Market (continued)
China—Healthcare VC Investment Trend
Growth Opportunity 3—Off-the-shelf iPSC-based Platforms for Cancer Immunotherapy that Targets Solid Tumors
Growth Opportunity 3—Off-the-shelf iPSC-based Platforms for Cancer Immunotherapy that Targets Solid Tumors (continued)
Growth Opportunity 4—Next-generation AAV for in Vivo Gene Therapy
Growth Opportunity 4—Next-generation AAV for in Vivo Gene Therapy (continued)
Growth Opportunity 5—AI for Quicker CGT Turnaround
Growth Opportunity 5—AI for Quicker CGT Turnaround (continued)
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-car...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | MG49-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1 |